CARTemis Therapeutics

CARTemis Therapeutics is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative chimeric antigen receptor (CAR) T-cell therapies specifically designed to combat solid tumors. The company's primary focus is overcoming the immunosuppressive tumor microenvironment (TME) and improving T-cell infiltration and persistence, which are significant hurdles in treating solid malignancies. Their lead candidate, a GPC3-targeted CAR-T, has demonstrated promising clinical activity in patients with advanced hepatocellular carcinoma. CARTemis leverages proprietary platforms to engineer next-generation cell therapies with enhanced safety and efficacy profiles, aiming to provide curative options for difficult-to-treat cancers such as liver, gastric, and pancreatic tumors.